Brief: Adaptimmune & Tcr² Therapeutics Announce Strategic Combination

Adaptimmune Therapeutics

06/03/2023 11:21

March 6 (Reuters) - Adaptimmune Therapeutics PLC
 ADAP.O :
    * ADAPTIMMUNE AND TCR² THERAPEUTICS ANNOUNCE STRATEGIC
COMBINATION
TO CREATE A PREEMINENT CELL THERAPY COMPANY FOR SOLID TUMORS
    * TCR2 THERAPEUTICS INC - FOLLOWING CLOSING OF TRANSACTION,
CASH
RUNWAY EXTENDED INTO 2026
    * TCR2 THERAPEUTICS INC - ADAPTIMMUNE SHAREHOLDERS WILL OWN
ABOUT
75% AND TCR² THERAPEUTICS STOCKHOLDERS WILL OWN ABOUT 25% OF
COMBINED COMPANY
    * TCR2 THERAPEUTICS INC - DEFINITIVE AGREEMENT UNDER WHICH
ADAPTIMMUNE WILL COMBINE WITH TCR² IN AN ALL-STOCK TRANSACTION
    * TCR2 THERAPEUTICS INC - TCR(2) STOCKHOLDERS WILL RECEIVE
1.5117
ADAPTIMMUNE ADS FOR EACH TCR(2) SHARE
    * TCR2 THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO
CONTINUE
TO TRADE ON NASDAQ STOCK MARKET UNDER SYMBOL "ADAP"
    * TCR2 THERAPEUTICS INC - COMBINED COMPANY HAS A TEAM OF
LEADING
CELL THERAPY EXPERTS LED BY ADRIAN RAWCLIFFE, CEO OF ADAPTIMMUNE

Source text for Eikon:  ID:nGNX1dl2XP 
Further company coverage:  ADAP.O 

 ((Reuters.Briefs@thomsonreuters.com;))